Latest Breaking News On - Reve technologies - Page 1 : comparemela.com

Autoimmune toxicities, while common following treatment with cancer immunotherapies, are not well-characterized in patients treated with BRAF/MEK inhibitors. Emerging data suggest that autoimmune effects may be linked with superior responses to both treatment modalities; however, there is little evidence describing mechanisms of immune-related toxicity for patients on BRAF/MEK inhibitors. Here we describe the experience of a 59-year-old HLA-A2, A29, B27-positive male patient with recurrent/metastatic melanoma. After progression on checkpoint inhibitor therapy, he was treated with dabrafenib/trametinib followed by encorafenib/binimetinib, which were well-tolerated. 18 months into BRAF/MEK inhibitor therapy, he developed a series of sudden-onset, severe toxicities including bilateral panuveitis, cytopenias, joint pain, skin rash, hypercalcemia and interstitial nephritis, which led to BRAF/MEKi cessation. At that time, the patient was found to have a complete response, which is ongoing at

Chiarion sileniYehs vogt koyanagi haradaBrafi mekiHomet morenoDummerr development of encorafenibUveitis study groupEmory universityUniversity of south carolinaV foundation translational awardEve technologies corporation albertaInstitutional review board at emory universityCytokine profileInstitutional review boardMedical universitySouth carolinaHuman discovery